Inmune Bio Stock Probability Of Bankruptcy

INMB Stock

USD 8.37 0.43 4.89%

INmune Bio's chance of distress is under 13% at the present time. It has tiny odds of undergoing some form of financial distress in the near future. Chance of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the INmune balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out INmune Bio Piotroski F Score and INmune Bio Altman Z Score analysis.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

The current year's Enterprise Value is expected to grow to about 185.9 M, whereas Market Cap is forecasted to decline to about 101.6 M.

INmune Bio Company chance of distress Analysis

INmune Bio's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current INmune Bio Probability Of Bankruptcy

Less than 13%

Most of INmune Bio's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, INmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of INmune Bio probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting INmune Bio odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of INmune Bio financial health.

Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.67)

Revenue Per Share

0.009

Quarterly Revenue Growth

(0.71)

Return On Assets

(0.27)

Return On Equity

(0.61)

The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Net Debt	Net Receivables	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Intangible Assets	Capital Stock	Current Deferred Revenue	Property Plant Equipment	Long Term Debt	Long Term Debt Total
Total Assets		0.99	0.92	-0.78	0.72	0.87	0.88	0.98	0.31	-0.97	0.9	0.72	0.43	0.97	0.95	-0.25	0.31	0.87	0.89	-0.54	-0.54
Total Stockholder Equity	0.99		0.89	-0.74	0.67	0.84	0.83	0.96	0.26	-0.96	0.87	0.72	0.36	0.95	0.94	-0.22	0.26	0.86	0.84	-0.47	-0.47
Net Tangible Assets	0.92	0.89		-0.92	0.9	0.97	0.96	0.92	0.61	-0.95	0.8	0.71	0.69	0.93	0.89	-0.57	0.61	0.94	0.93	-0.71	-0.71
Retained Earnings	-0.78	-0.74	-0.92		-0.99	-0.98	-0.94	-0.75	-0.8	0.76	-0.71	-0.79	-0.89	-0.75	-0.68	0.74	-0.8	-0.89	-0.82	0.91	0.91
Accounts Payable	0.72	0.67	0.9	-0.99		0.96	0.92	0.69	0.86	-0.71	0.65	0.76	0.93	0.7	0.62	-0.81	0.86	0.85	0.8	-0.92	-0.92
Capital Surpluse	0.87	0.84	0.97	-0.98	0.96		0.96	0.84	0.72	-0.86	0.78	0.81	0.8	0.84	0.79	-0.67	0.71	0.93	0.86	-0.83	-0.83
Total Liab	0.88	0.83	0.96	-0.94	0.92	0.96		0.89	0.63	-0.88	0.86	0.67	0.76	0.89	0.85	-0.59	0.63	0.87	0.93	-0.82	-0.82
Total Current Assets	0.98	0.96	0.92	-0.75	0.69	0.84	0.89		0.27	-0.98	0.92	0.59	0.41	0.99	0.98	-0.21	0.27	0.86	0.92	-0.52	-0.52
Common Stock	0.31	0.26	0.61	-0.8	0.86	0.72	0.63	0.27		-0.33	0.18	0.62	0.94	0.28	0.2	-0.95	1.0	0.57	0.5	-0.82	-0.82
Net Debt	-0.97	-0.96	-0.95	0.76	-0.71	-0.86	-0.88	-0.98	-0.33		-0.86	-0.6	-0.42	-0.99	-0.98	0.3	-0.33	-0.89	-0.91	0.49	0.49
Net Receivables	0.9	0.87	0.8	-0.71	0.65	0.78	0.86	0.92	0.18	-0.86		0.49	0.42	0.92	0.9	-0.16	0.18	0.78	0.79	-0.6	-0.6
Short Long Term Debt	0.72	0.72	0.71	-0.79	0.76	0.81	0.67	0.59	0.62	-0.6	0.49		0.62	0.55	0.49	-0.49	0.61	0.71	0.61	-0.66	-0.66
Short Term Debt	0.43	0.36	0.69	-0.89	0.93	0.8	0.76	0.41	0.94	-0.42	0.42	0.62		0.42	0.32	-0.89	0.94	0.66	0.59	-0.96	-0.96
Net Invested Capital	0.97	0.95	0.93	-0.75	0.7	0.84	0.89	0.99	0.28	-0.99	0.92	0.55	0.42		0.99	-0.26	0.28	0.86	0.92	-0.51	-0.51
Net Working Capital	0.95	0.94	0.89	-0.68	0.62	0.79	0.85	0.98	0.2	-0.98	0.9	0.49	0.32	0.99		-0.19	0.19	0.82	0.88	-0.42	-0.42
Intangible Assets	-0.25	-0.22	-0.57	0.74	-0.81	-0.67	-0.59	-0.21	-0.95	0.3	-0.16	-0.49	-0.89	-0.26	-0.19		-0.95	-0.52	-0.41	0.74	0.74
Capital Stock	0.31	0.26	0.61	-0.8	0.86	0.71	0.63	0.27	1.0	-0.33	0.18	0.61	0.94	0.28	0.19	-0.95		0.56	0.5	-0.81	-0.81
Current Deferred Revenue	0.87	0.86	0.94	-0.89	0.85	0.93	0.87	0.86	0.57	-0.89	0.78	0.71	0.66	0.86	0.82	-0.52	0.56		0.78	-0.7	-0.7
Property Plant Equipment	0.89	0.84	0.93	-0.82	0.8	0.86	0.93	0.92	0.5	-0.91	0.79	0.61	0.59	0.92	0.88	-0.41	0.5	0.78		-0.64	-0.64
Long Term Debt	-0.54	-0.47	-0.71	0.91	-0.92	-0.83	-0.82	-0.52	-0.82	0.49	-0.6	-0.66	-0.96	-0.51	-0.42	0.74	-0.81	-0.7	-0.64		1.0
Long Term Debt Total	-0.54	-0.47	-0.71	0.91	-0.92	-0.83	-0.82	-0.52	-0.82	0.49	-0.6	-0.66	-0.96	-0.51	-0.42	0.74	-0.81	-0.7	-0.64	1.0

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	(0.72)	(0.37)	(0.3)	(0.35)	(0.53)	(0.55)
Net Debt	(6.8M)	(21.8M)	(59.6M)	(36.8M)	(25.4M)	(26.7M)
Total Current Liabilities	700.4K	1.8M	4.4M	10.9M	18.5M	19.4M
Non Current Liabilities Total	160.2K	126.3K	15.4M	10.8M	397.0K	377.1K
Total Assets	24.5M	40.7M	99.9M	81.8M	57.0M	41.6M
Total Current Assets	7.8M	24.0M	82.6M	64.7M	39.9M	27.2M
Total Cash From Operating Activities	(5.4M)	(8.9M)	(28.5M)	(22.7M)	(12.0M)	(12.6M)

	Return On Equity	-0.61
	Return On Asset	-0.27
	Operating Margin	(299.25) %
	Current Valuation	126.27 M
	Shares Outstanding	18.2 M
	Shares Owned By Insiders	34.56 %
	Shares Owned By Institutions	13.70 %
	Number Of Shares Shorted	1.53 M
	Price To Earning	(7.51) X
	Price To Book	4.91 X
	Price To Sales	1,208 X
	Revenue	155 K
	Gross Profit	374 K
	EBITDA	(29.74 M)
	Net Income	(30.01 M)
	Cash And Equivalents	61.21 M
	Cash Per Share	3.41 X
	Total Debt	10.44 M
	Debt To Equity	0.22 %
	Current Ratio	30.87 X
	Book Value Per Share	2.08 X
	Cash Flow From Operations	(11.98 M)
	Short Ratio	22.49 X
	Earnings Per Share	(1.67) X
	Target Price	19.67
	Number Of Employees	11
	Beta	1.95
	Market Capitalization	152.36 M
	Total Asset	57 M
	Retained Earnings	(121.02 M)
	Working Capital	21.48 M
	Current Asset	8.38 M
	Current Liabilities	721.01 K
	Net Asset	57 M

	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA

Inmune Bio Stock Probability Of Bankruptcy

INmune Bio Company chance of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current INmune Bio Probability Of Bankruptcy

INmune Probability Of Bankruptcy Driver Correlations

INmune Probability Of Bankruptcy Peer Comparison

INmune Bio Main Bankruptcy Drivers

INmune Fundamentals

About INmune Bio Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for INmune Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY